CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- 4 Open-market sale Chief Executive Officer sold 125,309 shares at an average $132.34 ($16,583,634)
- 4 Open-market sale Chief Executive Officer sold 83,359 shares at an average $182.37 ($15,202,048)
- 4 Open-market sale Chief Executive Officer sold 69,216 shares at an average $71.82 ($4,971,360)
- 4 Open-market sale Chief Executive Officer sold 70,855 shares at an average $152.13 ($10,778,877)
- 4 Open-market sale CMO, Hematology sold 21,000 shares at an average $332.42 ($6,980,771)
- 4 Open-market sale Chief Executive Officer sold 67,481 shares at an average $94.83 ($6,399,303)
- 4 Open-market sale Chief Executive Officer sold 123,821 shares at an average $117.22 ($14,514,637)
- 4 Open-market sale President, COO & GM China sold 10,180 shares at an average $325.53 ($3,313,927)
- 4 Open-market sale Director sold 4,848 shares at an average $348.15 ($1,687,852)
- 4 Open-market sale Chief Financial Officer sold 308 shares at $349.06 ($107,512)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale CMO, Hematology sold 1,925 shares at an average $354.97 ($683,323)
- 4 Open-market sale Global Head of R&D sold 455 shares at $362.48 ($164,930)
- 4 Open-market sale CFO & Chief Strategy Officer sold 446 shares at $365.00 ($162,790)
- 4 Grant or award Director acquired 7,800 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 146,250 shares (grant or award)
- 4 Grant or award Director acquired 39,000 shares (grant or award)
- 4 Open-market sale President, COO & GM China sold 1,156 shares at $330.93 ($382,551)
- 4 Open-market sale Global Head of R&D sold 802 shares at $331.15 ($265,583)
- 4 Open-market sale CMO, Hematology sold 469 shares at $325.66 ($152,733)
Page 15 of 29 · 580 filings